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Abstract
Introduction
 Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder (FGID) that 
is classically characterized by recurrent abdominal pain or discomfort associated 
with alterations in bowel habits. 
 3 subtypes of IBS: IBS-D (diarrhea predominant), IBS-C (predominant constipation) 
and IBS-M (mix of diarrhea & constipation). Pathophysiology is multifactorial, but 
common triggers include an acute GI infection & food.   
 Those with IBS & comorbid depression often experience decreased quality of life 
(QOL) due to chronic abdominal pain & an increase in healthcare costs (Sibelli et al, 
2016). 
 There is a two-way communication that takes place between the intestinal wall & 
the CNS via the vagus nerve, which runs from the brainstem to the gut, and is 
responsible for relaying essential stress-response signals. This explains why CNS 
disorders are so often accompanied by digestive issues, & irregularities in the 
digestive system directly shape both cognitive & emotional states. 
 Depression-induced slow colonic motility is likely to compound the severity of gut 
dysfunction & go on to further destabilize the intestinal microbiota, which results in 
patients with IBS having instability of the microbiota (Park et al, 2013). The 
destabilization of the microbiota may then contribute to gut dysfunction as well as 




Applicability to Clinical Practice
Acknowledgements
Discussion
WHAT IS THE LINK BETWEEN IBS AND DEPRESSION?
 The pathophysiology of IBS is complex, however it is probable that dysfunction 
of the brain-gut pathways contributes to the appearance of the disease.  
 Those with IBS & depression display an imbalance of the inflammatory response, 
which then leads to the induction of the corresponding digestive and psychiatric 
symptoms. (Jizhong, Qiaomin, Chao & Yanqing, 2016).  
 Patients with IBS have been discovered to have altered gut microbiota 
(Muscatello, Bruno, Mento, Pandolfo & Zoccali, 2016). 
 Other studies have eluded to the concept that psychiatric symptoms occur before 
IBS symptoms present (Sibelli et al, 2016). 
WHAT ARE THE CAUSAL MECHANISMS FOR TRIGGERS OF IBS SYMPTOMS?
 External stressors or early life stressors (Sibelli et al, 2016).
 Feelings of anger, anxiety & depression have been linked to visceral and pain 
hypersensitivity (Muscatello et al., 2016).     
 The mood disorder may precedes the FGID symptoms, or vice versa (Koloski et 
al., 2016).  
 Anxiety & depression may increase a person’s risk of developing IBS in the 
future, however findings suggest that these are not the singular cause of IBS 
(Sibelli et al, 2016). 
 Acute GI infections are another common trigger for IBS (Sibelli et al., 2016). 
WHAT ARE THE BEST TREATMENT OPTIONS FOR PATIENTS WITH IBS & 
COMORBID DEPRESSION? 
 There is no standardized method to cure IBS. 
 For some, decreasing the burden of symptoms from IBS may be as simple as 
increasing physical activity & dietary modifications. Patients are usually advised 
to follow the low FODMAP diet, as it is a beneficial treatment of IBS. 
 TCAs can improve global symptoms of IBS and there is insufficient evidence to 
confirm the effectiveness of SSRIs. Some patients may still prefer SSRIs solely 
for their depression symptoms (Xie et al, 2015).
 Probiotics have been speculated to improve IBS symptoms via their effects 
intestinal immune function, visceral hypersensitivity, gastrointestinal motility, 
intestinal permeability & microbiota (Vanuytsel et al., 2014). This is especially 
with the Bifidobacterium infantis strand, which was found to be more effective in 
decreasing abdominal pain when compared to Lactobacillus salivarius (Vanuytsel
et al., 2014). 
 Other pharmacologic options for symptom relief include antispasmodics for the 
IBS-D subclass, & laxatives for the IBS-C subclass. 
 Some alternative medicine options that have been studied and appear promising 
for IBS symptom relief, including herbs, hypnotherapy & acupuncture. 
 Irritable bowel syndrome & depression are common comorbidities, however there is 
a wide variability regarding the appropriate treatment regimens for these patients. 
 IBS is classified as a functional bowel disease in which patients suffer from 
recurrent abdominal pain or discomfort associated with alterations in bowel habits. 
 While the cause of IBS is multifactorial, studies have revealed that the dysfunction 
of the brain-gut pathways are a culprit to disease appearance and progression, as 
seen in the biopsychosocial model of IBS. This model proposes that abdominal 
symptoms secondarily impact anxiety & depression symptoms and that 
psychological factors influence physiologic aspects such as motor functions, sensory 
threshold & stress reactivity of the gut through the vagal & sympathetic afferents. 
 Due to the complexity of the causal mechanisms that produce symptoms of IBS with 
depression, there is some uncertainty regarding the best treatment regimen for these 
patients. 
 Commonly, patients are advised to increase physical activity, reduce stress & 
implement dietary modifications. Pharmacotherapy may be advised for some, 
depending on their symptoms, & may include antidepressants, antispasmodics or 
laxatives. 
 There is not a standardized method of treating IBS with comorbid depression, 
therefore symptom management must be performed on a patient-by-patient basis. 
 What is the link between IBS & depression?
 What are the causal mechanisms for triggers of IBS symptoms?
 What are the best treatment options for patients with IBS & comorbid depression?   
 Importance of screening & treating anxiety/depression in patients with IBS, as psychological factors 
play an important role in symptom severity & persistence, as well as motivation to seek treatment 
and one’s response to treatment. 
 Educating patients on disease process & how to better manage their symptoms would ideally be the 
first step in creating their personalized treatment regimen. 
 The symptoms of IBS can be overwhelming for patients, so it is important to reiterate that even 
though their IBS is causing them a great deal of pain & discomfort, it does not cause permanent 
harm to their bowels or lead to cancer. 
 Be aware of potential predisposing factors of IBS. 
 Some options for treatment include lifestyle modifications such as increasing physical activity, 
decreasing stress & dietary modifications. Patients may also benefit from probiotics or alternative 
medicine such as hypnotherapy or acupuncture. 
 There may be a need for antidepressants, antispasmodics or laxatives. 
 There is not a one size fits all approach to treatment of these patients, so often it is a process of 
trial and error. It is important that the primary provider is aware of the communities 
resources, as well as when and where to refer patients if needed. 
 These patients often suffer from a decreased QOL & may be frustrated through the trials of finding 
an ideal treatment regimen. It is therefore imperative for a provider to be patient, supportive & 
evoke hope that an improved QOL through symptom management is obtainable. 
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Statement of the Problem
 Although IBS & depression are common comorbidities of one another, there is still 
uncertainty on how to best treat these patients. 
 There is also uncertainty in regards to whether IBS symptoms aggravate a patient's 
depression versus depression exacerbating the IBS symptoms.
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PATHOPHYSIOLOGY OF IBS AND DEPRESSION
 The biopsychosocial model describes how IBS pathophysiology may be due to various 
interactions between biological & psychosocial factors. External stressors & major life 
events may interrupt the regulation of the brain-gut axis & ultimately influence IBS onset, 
symptom severity and treatment response. The abdominal symptoms may also 
secondarily impact anxiety/depression symptoms (Sibelli et al., 2016). 
 Up to 60% of those with FGIDs suffer from psychiatric comorbidities (Park et al., 
2013).
 Stress can lead to abnormal GI motility and visceral hypersensitivity through modulation 
of the HPA axis. With this, there is an abnormal expression of corticotropin releasing 
factor (CRF), & an increase in CRF expression can lead to anxiety &/or depression. 
Those with IBS & depression exhibit an imbalance of the inflammatory response, which 
in turn, leads to the induction of the corresponding digestive & psychiatric symptoms. 
Therefore, the increased CRF expression that leads to anxiety &/or depression also 
contributes to IBS symptoms (Jizhong, Qiaomin, Chao & Yanqing, 2016). 
 Gut microbiota is altered in IBS patients, & it is still uncertain whether this dysbiosis
initiates anxiety & depressive symptoms (by increased gut permeability, secretion of 
endotoxin and/or neuropeptides, inflammation, altered nutrient absorption, & autonomic 
nervous system modulation) or if anxiety & depression prompt gastrointestinal disorders 
(Muscatello, Bruno, Mento, Pandolfo & Zoccali, 2016).  
CAUSAL MECHANISMS FOR TRIGGERS OF IBS SYMPTOMS
 Genetic predispositions & early-life stressors (physical/sexual/emotional abuse, death 
of a parent, parental divorce, etc.) could impact the bidirectional pathways between gut & 
brain. This will, in turn, influence one’s susceptibility to develop IBS, with the 
unfortunate possibility of each successive exposure to stressors exacerbating the IBS 
symptoms. 
 Anger, anxiety & depression have been linked to visceral & pain hypersensitivity. With 
the occurrence of negative emotions, visceral sensations are often more noticeable & 
considered to be painful (Muscatello et al., 2016). 
 Koloski, Jones & Talley (2016) calculated that in 1/3 of people a mood disorder 
precedes FGID, and in 2/3 of people a FGID precedes the mood disorder. 
 Conversely, Sibelli et al (2016) concluded that the overall risk of developing IBS was 
double for subjects that had anxiety &/or depression at baseline compared to those who 
did not. This study also goes on to explain that even though anxiety & depression may 
increase a person’s risk of developing IBS in the future, findings suggest that these are 
not the singular cause of IBS. 
 A common trigger for disease onset is an acute GI infections, with studies estimating 
around 5-32% of patients developing their IBS after suffering from a GI infection (Sibelli
et al., 2016). This is often termed as post infectious IBS, or PI-IBS. 
 Anxiety in IBS patients was more pronounced for those with several comorbidities, 
especially in younger adults. Depression displayed the same pattern as anxiety, & there 
was no significant relation between age & medical comorbidities in predicting IBS 
symptom severity or QOL (Thakur, Quigley, El-Serag, Gudleski & Lackner, 2016). 
CURRENT TREATMENT OPTIONS FOR IBS PATIENTS WITH COMORBID DEPRESSION
 There is no universally accepted method to cure IBS, & the subcategories of this 
disease complicate blanket treatment options. 
 Treatment is individualized to the patient’s most bothersome symptoms.  
 IBS symptoms, disease specific QOL, fatigue, depression/anxiety were all improved with 
physical activity when compared to baseline (Johannesson, Ringstrӧm, Abrahamsson & 
Sadik, 2015). 
 It is recommended that patients follow the low fermentable oligosaccharides, 
disaccharides, monosaccharides and polyols (FODMAP) diet. 
 Antidepressants are often recommended as a form of treatment, & it was discovered that 
tricyclic antidepressants can improve global symptoms of IBS & that there was 
insufficient evidence to confirm the effectiveness of selective serotonin reuptake 
inhibitors (Xie et al, 2015). 
 There may be some improvement in the global symptoms of IBS with the use of 
probiotics, specifically the use of the Bifidobacterium infantis strand, which was found 
to be more effective in decreasing abdominal pain when compared to Lactobacillus 
salivarius (Vanuytsel, Tack & Boeckxstaens, 2014). 
 Other options include antispasmodics for IBS-D & laxatives for IBS-C. 
 Berberine hydrochloride, a traditional Chinese herb, reduces anxiety & depression scores 
as well as IBS-D symptoms and overall QOL (Chen et al., 2015). 
 Gut-directed hypnotherapy displayed superior efficacy to the FODMAP diet on 
psychological indices & GI symptoms (Peters, Yao, Philpott, Yelland, Muir & Gibson, 
2016). 
 Moxibustion can significantly improve the symptoms of D-IBS, & may be more effective 
than EA in these patients (Zhao et al., 2015).
(Eisenstein, 2016)
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